Everstone Group to invest up to $50 mln in Slayback Pharma
The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma.
The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma.
Copyright PEI Media
Not for publication, email or dissemination